Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Drop in Short Interest

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) saw a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 57,707 shares, a decline of 21.8% from the February 12th total of 73,787 shares. Currently, 2.8% of the shares of the company are short sold. Based on an average daily trading volume, of 59,146 shares, the days-to-cover ratio is presently 1.0 days. Based on an average daily trading volume, of 59,146 shares, the days-to-cover ratio is presently 1.0 days. Currently, 2.8% of the shares of the company are short sold.

Institutional Trading of Acurx Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new position in Acurx Pharmaceuticals in the 4th quarter worth approximately $27,000. Geode Capital Management LLC bought a new position in Acurx Pharmaceuticals in the 4th quarter worth approximately $31,000. Millennium Management LLC purchased a new stake in Acurx Pharmaceuticals during the 4th quarter valued at approximately $103,000. Finally, Armistice Capital LLC purchased a new stake in Acurx Pharmaceuticals during the 2nd quarter valued at approximately $551,000. Institutional investors own 11.53% of the company’s stock.

Acurx Pharmaceuticals Stock Performance

ACXP opened at $3.88 on Friday. The stock has a market cap of $9.89 million, a price-to-earnings ratio of -0.69 and a beta of -1.16. The firm’s fifty day moving average is $2.39 and its 200 day moving average is $3.81. Acurx Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $21.00.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.70. On average, equities research analysts predict that Acurx Pharmaceuticals will post -0.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ACXP. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Wednesday, January 21st. Wall Street Zen raised shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 28th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $31.00.

Acurx Pharmaceuticals News Roundup

Here are the key news stories impacting Acurx Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — Acurx reported a narrower-than-expected loss for Q4 (EPS -$0.31 vs. consensus -$1.01) and filed a business update and full-year/quarter release. This beat and the company release are supportive. Press Release
• Positive Sentiment: Stronger cash position and clinical progress highlighted in the company update — management cited improved cash runway and clinical program advancement, which are key value drivers for a late-stage biotech. Cash & Clinical Update
• Neutral Sentiment: Analyst model updates from HC Wainwright — the firm provided quarterly EPS forecasts for 2026 (Q1 -$0.59, Q2 -$0.63, Q3 -$0.70, Q4 -$0.75) and a full-year outlook in line with consensus (~-$0.89). These estimates give investors modeling guidance but don’t change the narrative that Acurx remains loss-making.
• Neutral Sentiment: Earnings materials and transcript available — the Q4 2025 earnings call transcript and coverage (earnings schedule) are posted for investors reviewing management commentary and clinical milestones. Earnings Transcript
• Negative Sentiment: Ongoing unprofitability and continued negative EPS guidance — despite the Q4 beat, analysts (HC Wainwright and consensus) forecast persistent losses through 2026, which can cap valuation and keep selling pressure on the stock.
• Negative Sentiment: Micro‑cap volatility and market mechanics — Acurx’s very small market cap (~$9.9M), wide 12‑month trading range and low liquidity increase downside risk and make the stock sensitive to profit-taking and headline noise. The short-interest entry appears inconsistent in reporting but elevated short activity or perception of shorting could amplify downward moves.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).